Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Nura reveals neuroprotective lead target, first part of its neurology one-two punch

Nura aims to prevent axon degeneration, preserve neurons starting with an axon death switch

Nura Bio emerged from stealth last week with a $73 million series A and strategy to tackle neurological disorders based on two prevailing theories -- increasing neuroprotection and reducing neuroinflammation. Led by Vir and Biogen veteran Alpna Seth, the South San Francisco company is developing a small molecule that inhibits SARM1, an axon death switch.

The Column Group, which founded Nura Bio Inc. in

Read the full 647 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers